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irritated 7.9%, persistent crying over 3hours 0.5%, and drowsi-
ness/sleepiness 0.5%. Eleven serious adverse events were reported,
mostly infections of the lower respiratory tract; none were consid-
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afety and reactogenicity of the 10-valent pneumococcal non-
ypeable Haemophilus inﬂuenzae protein D conjugate vaccine
PHiD-CV) co-administered with DTPa-HBV-IPV/Hib in Viet-
amese infants
.N. Huu1,∗, N.T. Toan1, H.M. Tuan2, H.L. Viet2, P.L. Thanh Binh2,
.-W. Yu3, F. Shaﬁ4, A. Habib3, D. Borys3
Pasteur Institute, Ho Chi Minh City, Viet Nam
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Background: Pneumococcal infections are a major cause of
nfant mortality/morbidity in developing countries. This study
ssessed the safety and reactogenicity of PHiD-CV (SynﬂorixTM;
laxoSmithKline Biologicals) co-administered with DTPa-HBV-
PV/Hib (Infanrix hexaTM; GlaxoSmithKline Biologicals) to infants
n Vietnam, a developing country setting.
Methods: In this phase III, single centre, open-label study
NCT01153841), infants were randomised (2:1) to receive 3-dose
rimaryvaccinationat 2, 3 and4monthsof agewitheither PHiD-CV
o-administered with DTPa-HBV-IPV/Hib (PHiD-CV/Hx group), or
TPa-HBV-IPV/Hib alone (Control group). Solicited and unsolicited
dverse events (AEs) (any and grade 3)were recordedwithin 4 days
nd31days post-vaccination, respectively. SeriousAEs (SAEs)were
ecorded throughout the study. Safety analyseswere carried out on
he total vaccinated cohort.
Results: Between February and July 2011, 300 infants were
nrolled; 298 received betweenone and three vaccine doses (PHiD-
V/Hx group: n=199; Control group: n=99). Within 31 days
ost-vaccination, 8.2% and 3.0% of overall doses in the PHiD-CV/Hx
nd Control groups, respectively, were followed by ≥1 grade 3 AE
solicited and/or unsolicited, local and/or general). Within 4 days
ost-vaccination, the most frequent solicited local symptom was
ain (PHiD-CV/Hx group: 48.9% of doses; Control group: 31.0% of
oses) and the most frequent solicited general symptom was irri-
ability (PHiD-CV/Hx group: 58.0% of doses; Control group: 40.4% of
oses). Themost frequent grade 3 local symptomwas pain; follow-
ng 6.5% and 1.0% of doses in the PHiD-CV/Hx and Control groups,
espectively. Grade 3 solicited general symptoms were uncommon
n both groups (PHiD-CV/Hx group: ≤1.9% of doses; Control group:
0.3% of doses). Unsolicited symptoms were reported following
2.3% and 14.8% of doses in the PHiD-CV/Hx and Control groups,
espectively. Grade 3 unsolicited symptoms were reported follow-
ng ≤0.3% of doses; none were considered related to vaccination.
ifteen infants reported ≥1 SAE (PHiD-CV/Hx group: 9/199; Con-
rol group: 6/99); none were fatal; none were considered related
o vaccination.
Conclusion: A PHiD-CV 3-dose primary vaccination, co-
dministered with DTPa-HBV-IPV/Hib at 2, 3 and 4 months of age
as well tolerated by Vietnamese infants. PHiD-CV reactogenicity
as comparable to that observed in other South-East Asian popu-
ations.1,2
1Chevallier PIDJ 2009;28:S109-18.
2Kim PIDJ 2011;30:e235-43.
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Assessment of the immunogenicity and safety of Quinvaxem®
(DTwP-HepB- Hib) against diphtheria, pertussis, tetanus, hep-
atitis B and diseases caused by H. inﬂuenzae among healthy
Vietnamese children
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Background: An open, uncontrolled, single center, interven-
tional study, performed between March 2010 and September
2011 in nine villages in Long An province, Vietnam, to assess the
immunogenicity and safety of Quinvaxem® (DTwP-HepB-Hib) in
131 healthy children who had not previously received DTP vacci-
nation.
Methods: Subjects received three doses of Quinvaxem® using a
2-3-4 month schedule according to the local EPI. Immunogenicity
blood sampleswere collected at baseline, onemonth after the third
injection and one year after the ﬁrst injection. Solicited local and
systemic adverse events (AEs) and unsolicited AEs were collected
by active monitoring up to 30minutes post-vaccination and at 6,
24 and 48hours, 3 to 7 days and 28 days.
Results: Seroprotection rates were deﬁned as the percentage of
subjects with titers as follows: anti-diphtheria ≥0.1 IU/mL, anti-
tetanus ≥0.1 IU/mL, Hib ≥0.15g/mL, anti-HBs ≥10mIU/mL, and
anti-B. pertussis (seroconversion)≥20EU/mLor a four-fold increase
compared with baseline titers.
One month after the third dose, seroprotection rates for
hepatitis B and for diphtheria were both 93.1%, for tetanus
98.5%, for pertussis 99.2% (seroconversion) and for Hib was 100%
(≥0.15g/mL); 99.2% attained a Hib concentration of ≥1.0g/mL.
Twelvemonths after theﬁrst vaccination seroprotection rateswere
lower: hepatitis B 76.7%, diphtheria 88.4%, tetanus 82.2%, Hib 97.7%
(≥0.15g/mL) and pertussis 49.6% (seroconversion). This decline
in immunogenicity is in line with published data and is the reason
why some countries opt for a booster dose.
Overall incidence rates of swelling (≥5mm), redness (≥5mm),
and pain at the injection site were 5.6%, 2.8%, and 4.1%, respec-
tively (for all 392 injections). The incidence rates of systemic
AEs were: fever (38–38.9 ◦C, auxillary) 15.8%, fever (>39 ◦C) 2.6%,
refusal to suckle 2.6%, rash 0.3%, vomiting 1.0%, diarrhea 3.0%, easily
